Thiazolidinedione-induced fluid retention: Recent insights into the molecular mechanisms

PPAR Research

Volumn , Issue , 2013, Pages

  Bełtowski, Jerzy ^a   Rachańczyk, Jolanta ^a   Włodarczyk, Mirosław ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; AMILORIDE; ANGIOTENSIN II; AQUAPORIN 2; AQUAPORIN 4; BICARBONATE SODIUM COTRANSPORTER; BRADYKININ; CHLORIDE; CHLORIDE ION; DOPAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL SODIUM CHANNEL; FARGLITAZAR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; POTASSIUM ION; PROSTAGLANDIN; ROSIGLITAZONE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SODIUM; SODIUM ION; SODIUM PROTON EXCHANGE PROTEIN 3; UNINDEXED DRUG;

ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; DRUG MECHANISM; EXTRACELLULAR FLUID; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HUMAN; IN VIVO STUDY; INSULIN SENSITIVITY; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY COLLECTING TUBULE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; NATRIURESIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; SODIUM TRANSPORT; TRANSACTIVATION; URINE VOLUME; VASODILATATION;

EID: 84876548389     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2013/628628     Document Type: Article

References (44)

1. Jain A. K., Vaidya A., Ravichandran V., Kashaw S. K., Agrawal R. K.,. Recent developments and biological activities of thiazolidinone derivatives a review. Bioorganic & Medicinal Chemistry 2012 20 11 3378 3395 10.1016/j.bmc.2012.03.069
2. Cariou B., Charbonnel B., Staels B., Thiazolidinediones and PPAR γ agonists: time for a reassessment. Trends in Endocrinology & Metabolism 2012 23 5 205 215 10.1016/j.tem.2012.03.001
3. Kung J., Henry R. R., Thiazolidinedione safety. Expert Opinion on Drug Safety 2012 11 4 565 579 10.1517/14740338.2012.691963
4. Abbas A., Blandon J., Rude J., Elfar A., Mukherjee D., PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations. Cardiovascular & Hematological Agents in Medicinal Chemistry 2012 10 2 124 134 10.2174/187152512800388948
5. Bourg C. A., Phillips B. B., Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. The Annals of Pharmacotherapy 2012 46 2 282 289 10.1345/aph.1Q400
6. Wang F., Aleksunes L. M., Reagan L. A., Vergara C. M., Management of rosiglitazone-induced edema: two case reports and a review of the literature. Diabetes Technology and Therapeutics 2002 4 4 505 514 2-s2.0-0036379271 10.1089/152091502760306599
7. Nesto R. W., Bell D., Bonow R. O., Fonseca V., Grundy S. M., Horton E. S., Le Winter M., Porte D., Semenkovich C. F., Smith S., Young L. H., Kahn R., Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the american heart association and american diabetes association. Circulation 2003 108 23 2941 2948 2-s2.0-0344304678 10.1161/01.CIR.0000103683.99399.7E (Pubitemid 37517824)
8. Hollenberg N. K., Considerations for management of fluid dynamic issues associated with thiazolidinediones. American Journal of Medicine 2003 115 8 S111 S115 2-s2.0-0346219290 10.1016/j.amjmed.2003.09.018 (Pubitemid 37532902)
9. Patel C., Wyne K. L., McGuire D. K., Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diabetes and Vascular Disease Research 2005 2 2 61 66 2-s2.0-20444450632 (Pubitemid 40826997)
10. Yang T., Kidney-specific gene targeting: insight into thiazolidinedione-induced fluid retention. Nephrology 2006 11 3 201 206 2-s2.0-33744799047 10.1111/j.1440-1797.2006.00566.x (Pubitemid 43829438)
11. Tang W. H. W., Maroo A., PPAR γ agonists: safety issues in heart failure. Diabetes, Obesity and Metabolism 2007 9 4 447 454 2-s2.0-34347385042 10.1111/j.1463-1326.2006.00616.x (Pubitemid 47018508)
12. Karalliedde J., Buckingham R. E., Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Safety 2007 30 9 741 753 2-s2.0-34548316586 10.2165/00002018-200730090-00002 (Pubitemid 47347350)
13. Yang T., Soodvilai S., Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Research 2008 2008 8 2-s2.0-53149149804 10.1155/2008/943614 943614
14. Staruschenko A., Pavlov T. S., Imig J. D., Regulation of ENaC-mediated sodium reabsorption by peroxisome proliferator-activated receptors. PPAR Research 2010 2010 9 2-s2.0-77954592777 10.1155/2010/703735 703735
15. Yang B., Clifton L. G., McNulty J. A., Chen L., Brown K. K., Baer P. G., Effects of a PPAR γ agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats. Journal of Cardiovascular Pharmacology 2003 42 3 436 441 2-s2.0-0042338733 10.1097/00005344-200309000-00016 (Pubitemid 37071701)
16. Chen L., Yang B., McNulty J. A., Clifton L. G., Binz J. G., Grimes A. M., Strum J. C., Harrington W. W., Chen Z., Balon T. W., Stimpson S. A., Brown K. K., GI262570, a peroxisome proliferator-activated receptor γ agonist, changes electrolytes and water reabsorption from the distal nephron in rats. Journal of Pharmacology and Experimental Therapeutics 2005 312 2 718 725 2-s2.0-19944434103 10.1124/jpet.104.074088 (Pubitemid 40189571)
17. Song J., Knepper M. A., Hu X., Verbalis J. G., Ecelbarger C. A., Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. Journal of Pharmacology and Experimental Therapeutics 2004 308 2 426 433 2-s2.0-1642457244 10.1124/jpet.103.058008 (Pubitemid 38134200)
18. Zanchi A., Chiolero A., Maillard M., Nussberger J., Brunner H. R., Burnier M., Effects of the peroxisomal proliferator-activated receptor- γ agonist pioglitazone on renal and hormonal responses to salt in healthy men. Journal of Clinical Endocrinology and Metabolism 2004 89 3 1140 1145 2-s2.0-1642302410 10.1210/jc.2003-031526 (Pubitemid 38368402)
19. Umrani D. N., Banday A. A., Hussain T., Lokhandwala M. F., Rosiglitazone treatment restores renal dopamine receptor function in obese zucker rats. Hypertension 2002 40 6 880 885 2-s2.0-0036899151 10.1161/01.HYP.0000039963. 01288.D3 (Pubitemid 35434910)
20. Dobrian A. D., Schriver S. D., Khraibi A. A., Prewitt R. L., Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004 43 1 48 56 2-s2.0-0346157985 10.1161/01.HYP.0000103629.01745. 59 (Pubitemid 38031910)
21. Trivedi M., Marwaha A., Lokhandwala M., Rosiglitazone restores G-protein coupling, recruitment, and function of renal dopamine D1A receptor in obese Zucker rats. Hypertension 2004 43 2 376 382 2-s2.0-0842289896 10.1161/01.HYP.0000111587.51185.fe (Pubitemid 38174142)
22. Guan Y., Hao C., Cha D. R., Rao R., Lu W., Kohan D. E., Magnuson M. A., Redha R., Zhang Y., Breyer M. D., Thiazolidinediones expand body fluid volume through PPAR γ stimulation of ENaC-mediated renal salt absorption. Nature Medicine 2005 11 8 861 866 2-s2.0-23844472901 10.1038/nm1278 (Pubitemid 41161118)
23. Zhang H., Zhang A., Kohan D. E., Nelson R. D., Gonzalez F. J., Yang T., Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proceedings of the National Academy of Sciences of the United States of America 2005 102 26 9406 9411 2-s2.0-21544479710 10.1073/pnas.0501744102 (Pubitemid 40923576)
24. Hong G., Lockhart A., Davis B., Rahmoune H., Baker S., Ye L., Thompson P., Shou Y., O'Shaughnessy K., Ronco P., Brown J., PPAR γ activation enhances cell surface ENaC via up-regulation of SGK1 in human collecting duct cells. The FASEB Journal 2003 17 13 1966 1968
25. Pao A. C., SGK regulation of renal sodium transport. Current Opinion in Nephrology and Hypertension 2012 21 5 534 540 10.1097/MNH.0b013e32835571be
26. Spraggs C., McCarthy A., McCarthy L., Hong G., Hughes A., Lin X., Sathe G., Smart D., Traini C., Horn S. V., Warren L., Mosteller M., Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. Pharmacogenetics and Genomics 2007 17 12 1065 1076 2-s2.0-38449083331 10.1097/FPC.0b013e3282f1b2d7 (Pubitemid 351339491)
27. Artunc F., Sandulache D., Nasir O., Boini K. M., Friedrich B., Beier N., Dicks E., Pötzsch S., Klingel K., Amann K., Blazer-Yost B. L., Scholz W., Risler T., Kuhl D., Lang F., Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPAR γ agonist pioglitazone. Pflugers Archiv European Journal of Physiology 2008 456 2 425 436 2-s2.0-42049103429 10.1007/s00424-007-0401-5
28. + channel. Pflugers Archiv European Journal of Physiology 2005 451 3 445 453 2-s2.0-28344447828 10.1007/s00424-005-1477-4 (Pubitemid 41719576)
29. Borsting E., Cheng V. P., Glass C. K., Vallon V., Cunard R., Peroxisome proliferator-activated receptor- γ agonists repress epithelial sodium channel expression in the kidney. American Journal of Physiology 2012 302 5 F540 F551 10.1152/ajprenal.00306.2011
30. Vallon V., Hummler E., Rieg T., Pochynyuk O., Bugaj V., Schroth J., Dechenes G., Rossier B., Cunard R., Stockand J., Thiazolidinedione-induced fluid retention is independent of collecting duct ENaC activity. Journal of the American Society of Nephrology 2009 20 4 721 729 2-s2.0-65249106033 10.1681/ASN.2008040415
31. + channel. Molecular Pharmacology 2009 76 6 1333 1340 2-s2.0-73149107280 10.1124/mol.109.056911
32. Nofziger C., Brown K. K., Smith C. D., Harrington W., Murray D., Bisi J., Ashton T. T., Maurio F. P., Kalsi K., West T. A., Baines D., Blazer-Yost B. L., PPAR γ agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. American Journal of Physiology 2009 297 1 F55 F62 2-s2.0-67650661950 10.1152/ajprenal.00090.2009
33. Bełtowski J., Wójcicka G., Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research. Medical Science Monitor 2002 8 2 RA39 RA52 (Pubitemid 34218479)
34. Saad S., Agapiou D. J., Chen X. M., Stevens V., Pollock C. A., The role of Sgk-1 in the upregulation of transport proteins by PPAR- γ agonists in human proximal tubule cells. Nephrology Dialysis Transplantation 2009 24 4 1130 1141 2-s2.0-65349084594 10.1093/ndt/gfn614
35. Yoshioka K., Wakino S., Homma K., Kanda T., Tatematsu S., Hasegawa K., Sugano N., Ito O., Omata K., Saruta T., Hayashi K., Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR- γ ligands in ovariectomized obese rats. Obesity 2008 16 5 965 971 2-s2.0-42949111533 10.1038/oby.2008.18 (Pubitemid 351620461)
36. Endo Y., Suzuki M., Yamada H., Horita S., Kunimi M., Yamazaki O., Shirai A., Nakamura M., Iso- O. N., Li Y., Hara M., Tsukamoto K., Moriyama N., Kudo A., Kawakami H., Yamauchi T., Kubota N., Kadowaki T., Kume H., Enomoto Y., Homma Y., Seki G., Fujita T., Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPAR γ -dependent nongenomic signaling. Cell Metabolism 2011 13 5 550 561 10.1016/j.cmet.2011.02.015
37. Yogi A., 'Connor SE O., Callera G. E., Tostes R. C., Touyz R. M., Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension. Current Opinion in Nephrology and Hypertension 2010 19 2 169 176 10.1097/MNH.0b013e3283361c24
38. Bełtowski J., Lowicka E., EGF receptor as a drug target in arterial hypertension. Mini-Reviews in Medicinal Chemistry 2009 9 5 526 538 10.2174/138955709788167619
39. Jamroz-Wiśniewska A., Wójcicka G., Łowicka E., Ksiazek M., Bełtowski J., Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: role in leptin-induced hypertension. Biochemical Pharmacology 2008 75 8 1623 1638 10.1016/j.bcp.2008.01.003
40. +-ATPase. Peptides 2006 27 12 3234 3244 2-s2.0-33750961949 10.1016/j.peptides.2006.08.010 (Pubitemid 44738181)
41. Dewar B. J., Gardner O. S., Chen C. S., Earp H. S., Samet J. M., Graves L. M., Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones. Molecular Pharmacology 2007 72 5 1146 1156 2-s2.0-35548978112 10.1124/mol.107.037549 (Pubitemid 350012589)
42. + exchanger1(NHE1)-inhibition in troglitazone-induced growth arrest of breast cancer-derived cells MCF-7. Cellular Physiology and Biochemistry 2007 20 6 751 762 2-s2.0-35848965508 10.1159/000110435 (Pubitemid 350059719)
43. Goltsman I., Wang X., Lavallie E. R., Diblasio-Smith E. A., Ovcharenko E., Hoffman A., Abassi Z., Feuerstein G. Z., Winaver J., Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure. Circulation 2011 4 3 345 354 2-s2.0-79960580242 10.1161/CIRCHEARTFAILURE.110.960179
44. Agrawal R., Jain P., Dikshit S. N., Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist. Mini-Reviews in Medicinal Chemistry 2012 12 2 87 97 10.2174/138955712798995048